Nonetheless, it has been demonstrated that treatment with 4-hydroxy-tamoxifen, which is an ER modulator, reduces cellular proliferation more efficiently in p53 wild-type than mutant breast cancer cells [98], and fulvestrant, a molecule involved in ER degradation, is able to exert its function independently of p53 status [99]. Here, TP53 is linked to breast carcinoma.